On Wednesday, Biogen Inc (NASDAQ:BIIB) reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion. Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Also Read: Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says. Rare disease revenue decreased 4% year over year (down 4% CC) to $423.9 million. Spinraza’s revenue fell to $341.3 million from ...